Radioligand Binding Assay

Radioligand Binding Assay refers to an analytical technique used to quantify interactions between a ligand and a biological target such as a receptor, enzyme, transporter, or ion channel using a radioactively labelled ligand. This method enables sensitive measurement of binding affinity, receptor density, and competitive displacement, providing direct insight into molecular recognition and pharmacological mechanisms. Radioligand assays typically use isotopes such as tritium or iodine-125, measured through scintillation counting or gamma detection.

The pharmaceutical industry uses radioligand binding assays extensively in early drug discovery to confirm target engagement, assess selectivity, and support structure-activity relationship optimisation. Competitive binding assays determine whether a test compound displaces a known radioligand, enabling estimation of inhibitory constants and ranking of candidate molecules. Saturation binding experiments quantify receptor density and binding affinity parameters essential for understanding target biology and predicting pharmacodynamic behaviour. Radioligand assays also support quality control of biologics and receptor-binding therapeutics, although safety requirements for radioactive material handling and waste disposal impose operational constraints. As non-radioactive alternatives advance, radioligand binding assays remain highly valued for their sensitivity, established regulatory acceptance, and ability to provide precise quantitative pharmacology data critical for lead optimisation and mechanistic validation.